News
ProteLight Pharma Completed B Round Capital Raising of RMB 133 million

ProteLight Pharma Completed B Round Capital Raising of RMB 133 million

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. recently completed the Round B fund-raising of total RMB 133 million yuan, led by a well-known domestic VC firm with outstanding reputation focusing in the field of biological medicine, and jointly invested by local enterprises in Jiangyin. The financing capital of this round is mainly used for the research and development of antimicrobial peptide innovative drugs, the application of clinical approval, clinical trials and related costs of product manufacture. The success of this round of financing will speed up the development of innovative drugs and explore the research depth of antimicrobial peptides. Meanwhile, it will help to expand the influence of the company, market competitiveness and industry scale in the field of antimicrobial peptides. The antimicrobial peptide PL-5 spray project has now entered the Phase II clinical trial. The antimicrobial peptide PL-5 spray project was selected into the national“12th Five-Year Plan” and “13th Five-Year Plan”Mega-Projects for Innovative Drugs of China.

21

2018

/

11

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

September 3th, 2019, “Economic Daily News•China Economic Net” published an article named “ProteLight focuses on R & D of antimicrobial peptide new drugs -- declare war on superbugs", it tells the hard R&D process about Dr. Yuxin Chen, the Chairman of Board of ProteLight Pharma, lead his team to develop antimicrobial peptide new drugs.

05

2018

/

09

Dr. Yuxin Chen Received Peptide Application Special Award

Dr. Yuxin Chen Received Peptide Application Special Award

From July 4th to 6th, 2018, the15th Chinese International Peptide Sympossium was hold in Shenzhen. During the sympossium, Dr. Yuxin Chen, president of ProteLight Pharma, received the Peptide Application Special Awar for his outstanding contribution to peptide science.

10

2018

/

07

Can we win the battle with “Super Bacteria”?

Can we win the battle with “Super Bacteria”?

Lately, an article on internet named “A middle-aged man haunted by flu in Beijing” caused tremendous response, the author’s suffering is sympathetic and thought-provoking. Apart from problems in modern medical system, this article also reflects a sever challenge in biological and medical science. The patient infected with an unknown virus and antibiotics Super Bacteria, whose condition worsened and died within a month, whereas the modern medical science has nothing to do with it. In fact, clinical cases infected with Super Bacteria appeared occasionally in recent years, and its frequency has been arising and abuse of antibiotics has been forming a great threat to public health security in decades of years. Since appearance of medical science, human have been fighting with bacteria for thousands of years. Fleming found penicillin in 1928 that is a biological weapon comes from antinomyces and fungus, and it once made human had upper hand in the battle, however, along with antibiotics appearance and overgrowth of varied bacterial flora, human is losing is dominant position in the battle. It is reported that if this is situation develops, 30,000,000 people will die of drug-resistant bacteria until 2050[1].

02

2018

/

03

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

On December 27th, 2017, appraised by Jiangsu Province Personnel Work Leading Group and CPC Jiangsu Provincial Party Committee, ProteLight’s R & D team was finally named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017, which is the only Noble Prize Winner type’s Innovation and Entrepreneurship Team in this appraisal.

29

2017

/

12

Congratulate to ProteLight for Being Identified as Hi-Tech Enterprise

Congratulate to ProteLight for Being Identified as Hi-Tech Enterprise

On December7th, 2017, through strict appraisal by relevant higher authorities that Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was identified as Hi-Tech Enterprise, which strongly suggests that the government confirm ProteLight taking national category 1.1 new drug development as direction over the years, which is also an important signal of ProteLight’s technical level and products technology.

10

2017

/

12

ProteLight Pharma Held a Grand-breaking Ceremony of New Plant Construction

ProteLight Pharma Held a Grand-breaking Ceremony of New Plant Construction

On September 22th, 2017, the Grand-breaking Ceremony of ProteLight’s new plant construction opened, that locates at Xingao Road, Hi-Tech district, Jiangyin. The leaders of multiple departments of Jiangyin government and Dr. Yuxin Chen, chairman of Protelight’s board showed there. The new factory covers an area of 65,000 square meters, including production workshops, R&D centers and office buildings etc.

22

2017

/

09

ProteLight Pharma's Technical Consultant Received the Bruce Merrifield Award, the Most Prestigious Award in Polypeptide Research Field

ProteLight Pharma's Technical Consultant Received the Bruce Merrifield Award, the Most Prestigious Award in Polypeptide Research Field

During June 17th to 22th, 2017, the 25th American Peptide Symposium opened in Whistler, Canada, Dr. Robert Hodges, the technical consultant and shareholder of ProteLight Pharmaceuticals, received the most prestigious award in polypeptide research field, the Bruce Merrifield Award, for his outstanding lifetime achievement in peptide research, and his scientific creativity is the highest level in peptide field.

05

2017

/

07

< 123456 >